c-myc antisense oligonucleotide treatment ameliorates murine ARPKD

Kidney International

Volumn 61, Issue SUPPL. 1, 2002, Pages

  Ricker, Justin L ^a   Mata, John E ^a   Iversen, Patrick L ^a   Gattone II, Vincent H ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antisense oligonucleotide; c myc; C57BL 6J cpk cpk mice; Clusterin (SGP 2); EGF; PCNA; Polycystic kidney disease

Indexed keywords

EPIDERMAL GROWTH FACTOR; HISTONE; MYC PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BODY WEIGHT; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; HEMATOCRIT; IMMUNOBLOTTING; KIDNEY CYST; KIDNEY MASS; KIDNEY POLYCYSTIC DISEASE; KIDNEY TUBULE; MOUSE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UREA NITROGEN BLOOD LEVEL;

EID: 0036167712     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.0610s1125.x     Document Type: Conference Paper

References (45)

1. The severe perinatal form of autosomal recessive polycystic kidney disease maps to chromosome 6p21.1-p12: Implications for genetic counseling
2. Murine autosomal recessive polycystic kidney disease with multiorgan involvement induced by the cpk gene
3. Congenital polycystic kidney disease, genetically transmitted infantile polycystic kidney disease in C57BL/6J mice
4. Autosomal recessive polycystic kidney disease in a murine model, a gross and microscopic description
5. Elevated c-myc protooncogene expression in autosomal recessive polycystic kidney disease
6. Elevated proto-oncogenes expression in polycystic kidneys of the C57BL/6J (cpk) mouse
7. Localization of overexpressed c-myc mRNA in polycystic kidneys of the cpk mouse
8. Autosomal dominant polycystic kidney disease in the rat
9. Renal expression of a transforming growth factor-a transgene accelerates the progression of inherited, slowly progressive polycystic kidney disease in the mouse
10. The development of autosomal recessive polycystic kidney disease in BALB/c-cpk/cpk mice
11. c-myc as an inducer of polycystic kidney disease in transgenic mice
12. Polycystic kidney disease in SBM transgenic mice, role of c-myc in disease induction and progression
13. Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease (ADPKD)
14. Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease
15. Genomic sequencing
16. The SGP-2 gene is developmentally regulated in the mouse kidney and abnormally expressed in collecting duct cysts in polycystic kidney disease
17. Defective epidermal growth factor gene expression in mice with polycystic kidney disease
18. The many roles of c-myc in apoptosis
19. Myc oncogenes: The enigmatic family
20. C-myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms
21. Mutant p53 can provoke apoptosis in p53-deficient Hep3B cells with delayed kinetics relative to wild-type p53
22. C-myc-induced apoptosis in polycystic kidney disease is Bcl-2 and p53 independent
23. A role for c-myc in chemically induced renal cell death
24. Proto-oncogene expression in human glomerular diseases
25. Participation of cyclin A in myc-induced apoptosis
26. Cyst formation and growth in autosomal dominant polycystic kidney disease
27. Understanding human cystic disease through experimental models
28. Antisense oligonucleotides as therapeutic agents - Is the bullet really magical?
29. Does antisense exist?
30. Fluorescence microscopic comparison of the binding of phosphodiester and phosphorothioate (antisense) oligodeoxyribonucleotides to subcellular structures, including intermediate filaments, the endoplasmic reticulum, and the nuclear interior
31. Sequence-independent effects of phosphorothiolated oligonucleotides on synaptic transmission and excitability in the hippocampus in vivo
32. Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesis monkey
33. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey
34. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys
35. Toxicity of oligonucleotide therapeutic agents
36. Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys
37. Bolus intravenous injection of phosphorothioate oligonucleotides causes severe hypotension by acting as alpha-1 adrenergic receptor antagonists
38. Role of RNAse H in hybrid-arrested translation by antisense oligonucleotides
39. A specificity comparison of four antisense types: Morpholino, 2'-O-methyl RNA, DNA, and phosphorothioate DNA
40. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation
41. Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems
42. In vitro efficacy of morpholino-modified antisense oligomers directed against tumor necrosis factor-alpha mRNA
43. Comparison of efficacy of antisense oligomers directed toward TNF-alpha in helper T and macrophage cell lines
44. Antisense morpholino oligonucleotide analog induces missplicing of c-myc mRNA